WA
CLDX icon

Waverly Advisors’s Celldex Therapeutics CLDX Stock Holding History

Waverly Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7
Closed -$1K – 178
2015
Q3 		$1K Hold
7
– – ﹤0.01% 412
2015
Q2 		$3K Hold
7
– – ﹤0.01% 326
2015
Q1 		$3K Hold
7
– – ﹤0.01% 314
2014
Q4 		$2K Hold
7
– – ﹤0.01% 387
2014
Q3 		$1K Hold
7
– – ﹤0.01% 744
2014
Q2 		$2K Hold
7
– – ﹤0.01% 691
2014
Q1 		$2K Hold
7
– – ﹤0.01% 652
2013
Q4 		$2K Hold
7
– – ﹤0.01% 774
2013
Q3 		$4K Buy
+7
New +$2.4K ﹤0.01% 502

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Waverly Advisors's CLDX Position: Q4 2015 in Review

Waverly Advisors sold out of Celldex Therapeutics (CLDX) in Q4 2015, closing a stake of 7 shares — an estimated $1K sold.

Waverly Advisors first reported a position in CLDX in Q3 2013 and held it in 9 quarters. The position peaked at $4K in Q3 2013. 171 funds tracked by Wall St. Rank hold CLDX as of Q4 2015.

  • Waverly Advisors reported no remaining Celldex Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Waverly Advisors sold 7 Celldex Therapeutics shares in Q4 2015, an estimated $1K.
  • Waverly Advisors first reported a position in Celldex Therapeutics in Q3 2013 and held it in 9 quarters.
  • Waverly Advisors's Celldex Therapeutics position peaked at $4K in Q3 2013.
  • 171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2015.

Based on Waverly Advisors's 13F filing for Q4 2015, filed 8 Feb 2016.